文献速递血栓与止血

艾美赛珠单抗治疗获得性血友病A

Emicizumab for the treatment of acquired hemophilia A.
PubMed 文献 · Blood · 2021-01-01

本文报告12例获得性血友病A患者接受艾美赛珠单抗治疗的结果。患者中位年龄74岁,初始凝血因子VIII低于1%,8例有严重出血。艾美赛珠单抗起始剂量为每周3 mg/kg皮下注射2至3次,随后每3周1.5 mg/kg。首次给药后1至3天活化部分凝血活酶时间恢复正常,11天时凝血因子VIII(人试剂)超过10%,止血疗效在1.5天时获得并停止旁路治疗,115天时凝血因子VIII(牛试剂)超过50%提示完全缓解。结论认为艾美赛珠单抗似乎是获得性血友病A的有效止血治疗。

要点

  • 艾美赛珠单抗起始3 mg/kg皮下注射每周2至3次,后1.5 mg/kg每3周维持。
  • 首次给药后1至3天活化部分凝血活酶时间恢复正常,1.5天获得止血并停止旁路治疗。
  • 中位5次注射后,115天凝血因子VIII(牛试剂)超过50%提示完全缓解。

核心结论

  • 艾美赛珠单抗似乎是获得性血友病A的有效止血治疗,具有皮下给药、止血疗效好、可早期出院以及减少免疫抑制和不良事件的优点。

研究设计与样本

  • 本文报告6例男性和6例女性获得性血友病A患者接受艾美赛珠单抗治疗,所有数据以中位数和四分位距表示。

主要发现

  • 患者年龄74(64-80)岁,初始凝血因子VIII低于1%,抑制物滴度22.3 Bethesda单位(BU)/mL(范围3-2000),8例有严重出血。
  • 首次艾美赛珠单抗给药后1至3天活化部分凝血活酶时间恢复正常,凝血因子VIII(人试剂)在11(7.5-12)天后超过10%。
  • 止血疗效在1.5(1-4)天后获得并停止旁路治疗,凝血因子VIII(牛试剂)在115(67-185)天后超过50%提示完全缓解,艾美赛珠单抗在31(15-79)天后停止。
  • 中位注射5次(范围3-9),无患者死于出血或血栓栓塞,首次艾美赛珠单抗给药后未观察到突破性出血。

关键数值与推荐

  • 艾美赛珠单抗起始剂量为3 mg/kg皮下注射每周一次共2至3次,随后1.5 mg/kg每3周一次以维持最低有效凝血因子VIII水平。
  • 所有患者接受类固醇和/或利妥昔单抗免疫抑制治疗。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Acquired hemophilia A (AHA) is a severe bleeding disorder caused by inhibiting autoantibodies to coagulation factor VIII (FVIII). For hemostatic treatment, bypassing agents and human or porcine FVIII are currently standard of care. Emicizumab is a bispecific, FVIII-mimetic therapeutic antibody that reduced the annualized bleeding rates in congenital hemophiliacs. Here, we report on 6 male and 6 female patients with AHA treated with emicizumab (all data medians and interquartile range), age 74 (64-80) years, initial FVIII <1%; inhibitor titer 22.3 Bethesda units (BU)/mL (range, 3-2000). Eight patients had severe bleeding. Emicizumab was started, 3 mg/kg subcutaneously, weekly for 2 to 3 doses, followed by 1.5 mg/kg every 3 weeks to keep the lowest effective FVIII levels. For FVIII monitoring, chromogenic assays with human and bovine reagents were used. All patients received immunosuppression with steroids and/or rituximab. After the first dose of emicizumab, activated partial thromboplastin time normalized in 1 to 3 days, FVIII (human reagents) exceeded 10% after 11 (7.5-12) days. Hemostatic efficacy was obtained and bypassing therapy stopped after 1.5 (1-4) days. FVIII (bovine reagents) exceeded 50%, indicating complete remission after 115 (67-185) days, and emicizumab was stopped after 31 (15-79) days. A median of 5 injections (range, 3-9) were given. No patient died of bleeding or thromboembolism, and no breakthrough bleeding was observed after the first dose of emicizumab. In conclusion, emicizumab seems to be an effective hemostatic therapy for AHA, with the advantages of subcutaneous therapy, good hemostatic efficacy, early discharge, and reduction of immunosuppression and adverse events.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Knoebl P, Thaler J, Jilma P, et al. Emicizumab for the treatment of acquired hemophilia A. Blood. 2021. PMID: 32766881. doi:10.1182/blood.2020006315

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。